|
Gene: C3 |
Gene summary for C3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | C3 | Gene ID | 718 |
Gene name | complement C3 | |
Gene Alias | AHUS5 | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B4DR57 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
718 | C3 | CA_HPV_1 | Human | Cervix | CC | 2.81e-16 | -6.77e-01 | 0.0264 |
718 | C3 | CA_HPV_2 | Human | Cervix | CC | 5.69e-14 | -6.93e-01 | 0.0391 |
718 | C3 | CA_HPV_3 | Human | Cervix | CC | 1.59e-11 | -6.38e-01 | 0.0414 |
718 | C3 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 1.15e-05 | -3.77e-01 | 0.0208 |
718 | C3 | N_HPV_1 | Human | Cervix | N_HPV | 5.84e-08 | -5.69e-01 | 0.0079 |
718 | C3 | N_HPV_2 | Human | Cervix | N_HPV | 7.40e-09 | -5.13e-01 | -0.0131 |
718 | C3 | CCI_1 | Human | Cervix | CC | 4.72e-05 | -7.56e-01 | 0.528 |
718 | C3 | CCI_2 | Human | Cervix | CC | 2.04e-06 | -7.76e-01 | 0.5249 |
718 | C3 | CCII_1 | Human | Cervix | CC | 1.08e-10 | -7.53e-01 | 0.3249 |
718 | C3 | Tumor | Human | Cervix | CC | 2.51e-17 | -6.99e-01 | 0.1241 |
718 | C3 | sample1 | Human | Cervix | CC | 1.27e-03 | -8.83e-02 | 0.0959 |
718 | C3 | sample3 | Human | Cervix | CC | 1.11e-15 | -6.38e-01 | 0.1387 |
718 | C3 | L1 | Human | Cervix | CC | 5.63e-10 | -7.17e-01 | 0.0802 |
718 | C3 | T1 | Human | Cervix | CC | 7.61e-07 | 3.87e-02 | 0.0918 |
718 | C3 | T3 | Human | Cervix | CC | 1.15e-14 | -6.42e-01 | 0.1389 |
718 | C3 | AEH-subject1 | Human | Endometrium | AEH | 7.07e-65 | 1.25e+00 | -0.3059 |
718 | C3 | AEH-subject2 | Human | Endometrium | AEH | 1.57e-48 | 1.18e+00 | -0.2525 |
718 | C3 | AEH-subject3 | Human | Endometrium | AEH | 1.88e-35 | 8.97e-01 | -0.2576 |
718 | C3 | AEH-subject4 | Human | Endometrium | AEH | 1.17e-22 | 7.89e-01 | -0.2657 |
718 | C3 | EEC-subject2 | Human | Endometrium | EEC | 2.38e-40 | 1.01e+00 | -0.2607 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0070293 | Stomach | GC | renal absorption | 5/1159 | 17/18723 | 2.98e-03 | 2.66e-02 | 5 |
GO:0034379 | Stomach | GC | very-low-density lipoprotein particle assembly | 4/1159 | 11/18723 | 3.39e-03 | 2.94e-02 | 4 |
GO:00085443 | Stomach | GC | epidermis development | 33/1159 | 324/18723 | 3.43e-03 | 2.96e-02 | 33 |
GO:00099134 | Stomach | GC | epidermal cell differentiation | 23/1159 | 202/18723 | 3.50e-03 | 3.02e-02 | 23 |
GO:0002753 | Stomach | GC | cytoplasmic pattern recognition receptor signaling pathway | 10/1159 | 60/18723 | 3.53e-03 | 3.02e-02 | 10 |
GO:00060814 | Stomach | GC | cellular aldehyde metabolic process | 10/1159 | 60/18723 | 3.53e-03 | 3.02e-02 | 10 |
GO:0070423 | Stomach | GC | nucleotide-binding oligomerization domain containing signaling pathway | 6/1159 | 25/18723 | 3.55e-03 | 3.03e-02 | 6 |
GO:00092674 | Stomach | GC | cellular response to starvation | 19/1159 | 156/18723 | 3.63e-03 | 3.09e-02 | 19 |
GO:00316694 | Stomach | GC | cellular response to nutrient levels | 24/1159 | 215/18723 | 3.74e-03 | 3.18e-02 | 24 |
GO:00713835 | Stomach | GC | cellular response to steroid hormone stimulus | 23/1159 | 204/18723 | 3.96e-03 | 3.33e-02 | 23 |
GO:00305225 | Stomach | GC | intracellular receptor signaling pathway | 28/1159 | 265/18723 | 4.04e-03 | 3.39e-02 | 28 |
GO:00464862 | Stomach | GC | glycerolipid metabolic process | 38/1159 | 392/18723 | 4.15e-03 | 3.47e-02 | 38 |
GO:00485253 | Stomach | GC | negative regulation of viral process | 13/1159 | 92/18723 | 4.27e-03 | 3.54e-02 | 13 |
GO:00109594 | Stomach | GC | regulation of metal ion transport | 39/1159 | 406/18723 | 4.34e-03 | 3.58e-02 | 39 |
GO:0035872 | Stomach | GC | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 6/1159 | 26/18723 | 4.38e-03 | 3.60e-02 | 6 |
GO:0099024 | Stomach | GC | plasma membrane invagination | 17/1159 | 136/18723 | 4.41e-03 | 3.60e-02 | 17 |
GO:0002460 | Stomach | GC | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 35/1159 | 356/18723 | 4.64e-03 | 3.76e-02 | 35 |
GO:00072663 | Stomach | GC | Rho protein signal transduction | 17/1159 | 137/18723 | 4.75e-03 | 3.84e-02 | 17 |
GO:00469163 | Stomach | GC | cellular transition metal ion homeostasis | 15/1159 | 115/18723 | 4.87e-03 | 3.89e-02 | 15 |
GO:00515922 | Stomach | GC | response to calcium ion | 18/1159 | 149/18723 | 4.97e-03 | 3.96e-02 | 18 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0414520 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa0513416 | Cervix | CC | Legionellosis | 20/1267 | 57/8465 | 1.29e-04 | 8.19e-04 | 4.85e-04 | 20 |
hsa05152 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa051337 | Cervix | CC | Pertussis | 21/1267 | 76/8465 | 3.08e-03 | 1.19e-02 | 7.03e-03 | 21 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa05131110 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa04145110 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa0513417 | Cervix | CC | Legionellosis | 20/1267 | 57/8465 | 1.29e-04 | 8.19e-04 | 4.85e-04 | 20 |
hsa051521 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa0513312 | Cervix | CC | Pertussis | 21/1267 | 76/8465 | 3.08e-03 | 1.19e-02 | 7.03e-03 | 21 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa051504 | Cervix | HSIL_HPV | Staphylococcus aureus infection | 21/459 | 96/8465 | 2.93e-08 | 1.43e-06 | 1.16e-06 | 21 |
hsa0414523 | Cervix | HSIL_HPV | Phagosome | 27/459 | 152/8465 | 3.58e-08 | 1.50e-06 | 1.21e-06 | 27 |
hsa0514022 | Cervix | HSIL_HPV | Leishmaniasis | 18/459 | 77/8465 | 9.82e-08 | 3.14e-06 | 2.54e-06 | 18 |
hsa0513423 | Cervix | HSIL_HPV | Legionellosis | 12/459 | 57/8465 | 4.24e-05 | 6.21e-04 | 5.02e-04 | 12 |
hsa05322 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
hsa0513125 | Cervix | HSIL_HPV | Shigellosis | 27/459 | 247/8465 | 3.78e-04 | 3.49e-03 | 2.82e-03 | 27 |
hsa051522 | Cervix | HSIL_HPV | Tuberculosis | 19/459 | 180/8465 | 3.99e-03 | 2.39e-02 | 1.93e-02 | 19 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Breast | DCIS |
C3 | ITGAM_ITGB2 | C3_ITGAM_ITGB2 | COMPLEMENT | Breast | DCIS |
C3 | ITGAX_ITGB2 | C3_ITGAX_ITGB2 | COMPLEMENT | Breast | DCIS |
PTN | SDC3 | PTN_SDC3 | PTN | Breast | DCIS |
ANGPTL4 | SDC3 | ANGPTL4_SDC3 | ANGPTL | Breast | DCIS |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Breast | Healthy |
C3 | ITGAM_ITGB2 | C3_ITGAM_ITGB2 | COMPLEMENT | Breast | Healthy |
C3 | ITGAX_ITGB2 | C3_ITGAX_ITGB2 | COMPLEMENT | Breast | Healthy |
ANGPTL4 | SDC3 | ANGPTL4_SDC3 | ANGPTL | Breast | IDC |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Breast | IDC |
C3 | ITGAM_ITGB2 | C3_ITGAM_ITGB2 | COMPLEMENT | Breast | IDC |
C3 | ITGAX_ITGB2 | C3_ITGAX_ITGB2 | COMPLEMENT | Breast | IDC |
DSG2 | DSC3 | DSG2_DSC3 | DESMOSOME | Breast | IDC |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Cervix | ADJ |
C3 | ITGAM_ITGB2 | C3_ITGAM_ITGB2 | COMPLEMENT | Cervix | ADJ |
C3 | ITGAX_ITGB2 | C3_ITGAX_ITGB2 | COMPLEMENT | Cervix | ADJ |
PTN | SDC3 | PTN_SDC3 | PTN | Cervix | CC |
DSG2 | DSC3 | DSG2_DSC3 | DESMOSOME | Cervix | CC |
ANGPTL4 | SDC3 | ANGPTL4_SDC3 | ANGPTL | Cervix | CC |
C3 | C3AR1 | C3_C3AR1 | COMPLEMENT | Cervix | CC |
Page: 1 2 3 4 5 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C3 | SNV | Missense_Mutation | novel | c.2800N>C | p.Glu934Gln | p.E934Q | P01024 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
C3 | SNV | Missense_Mutation | c.1052C>T | p.Ser351Phe | p.S351F | P01024 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
C3 | SNV | Missense_Mutation | rs199911426 | c.4594N>T | p.Arg1532Trp | p.R1532W | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |
C3 | SNV | Missense_Mutation | c.4276N>A | p.Asp1426Asn | p.D1426N | P01024 | protein_coding | deleterious(0.01) | probably_damaging(0.929) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
C3 | SNV | Missense_Mutation | c.3803N>G | p.Ser1268Cys | p.S1268C | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
C3 | SNV | Missense_Mutation | c.1376N>T | p.Ser459Leu | p.S459L | P01024 | protein_coding | tolerated(0.09) | possibly_damaging(0.599) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
C3 | SNV | Missense_Mutation | novel | c.4408N>A | p.Glu1470Lys | p.E1470K | P01024 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C3 | SNV | Missense_Mutation | novel | c.3118G>C | p.Glu1040Gln | p.E1040Q | P01024 | protein_coding | tolerated(0.11) | benign(0.063) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
C3 | SNV | Missense_Mutation | novel | c.2782N>G | p.Ser928Ala | p.S928A | P01024 | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C3 | SNV | Missense_Mutation | c.1452N>T | p.Glu484Asp | p.E484D | P01024 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | Imprime PGG immunotherapeutic | |||
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | POT-4 | 19025129 | ||
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | COMPSTATIN | COMPSTATIN | 25494040 | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | POT-4 | |||
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | APL-2 | PEGCETACOPLAN | ||
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | clozapine | CLOZAPINE | 26503818 |
Page: 1 |